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Abstract
The miR-200b~200a~429 gene cluster is a key regulator of EMT and cancer metastasis, however the transcription-
based mechanisms controlling its expression during this process are not well understood. We have analyzed the
miR-200b~200a~429 locus for epigenetic modifications in breast epithelial and mesenchymal cell lines using
chromatin immunoprecipitation assays and DNA methylation analysis. We discovered a novel enhancer located
approximately 5.1kb upstream of the miR-200b~200a~429 transcriptional start site. This region was associated with
the active enhancer chromatin signature comprising H3K4me1, H3K27ac, RNA polymerase II and CpG dinucleotide
hypomethylation. Luciferase reporter assays revealed the upstream enhancer stimulated the transcription of the
miR-200b~200a~429 minimal promoter region approximately 27-fold in breast epithelial cells. Furthermore, we found
that a region of the enhancer was transcribed, producing a short, GC-rich, mainly nuclear, non-polyadenylated RNA
transcript designated miR-200b eRNA. Over-expression of miR-200b eRNA had little effect on miR-200b~200a~429
promoter activity and its production did not correlate with miR-200b~200a~429 gene expression. While additional
investigations of miR-200b eRNA function will be necessary, it is possible that miR-200b eRNA may be involved in
the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the
presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells.
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Introduction
MicroRNAs (miRNAs) are small noncoding RNAs that
regulate gene expression programs for a number of critical
cellular pathways, including stem cell identity, differentiation,
cell division and lineage commitment [1]. There is increasing
evidence that miRNAs can act as master regulators of
epithelial mesenchymal transition (EMT), an early
developmental process that is also linked to tumor cell
migration and the establishment of secondary metastases [2].
One such miRNA involved in EMT and cancer metastasis is the
miR-200 gene family. The miR-200 family comprises five
members (miR-200a, miR-200b, miR-200c, miR-141 and
miR-429), clustered and expressed as two separate
polycistronic pri-miRNA transcripts, with the
miR-200b~200a~429 gene cluster at chromosomal location
1p36 and miR-200c~141 cluster at chromosomal location
12p13 [3]. Numerous laboratories have shown that EMT is
induced by the loss of expression of the miR-200 family, which
enables maintenance of the epithelial phenotype [4–9]. A
double negative feedback-loop between the ZEB1/2
transcription factors and the miR-200 genes regulates the
induction of EMT and the reverse process, mesenchymal to
epithelial transition (MET) [4,5,7]. Although the promoter
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regions of the miR-200 genes are well defined [4], less is
known about the transcriptional mechanisms controlling the
expression of this particular gene family in epithelial cells.
Spatiotemporal control of gene expression is a complex
process involving the coordinated actions of transcription
factors, chromatin modifying enzymes as well as distinct
classes of functional genomic elements including promoters,
insulator elements and enhancers. Enhancers are proposed to
be the most abundant class of regulatory elements, comprising
up to 10% of the human genome [10]. Enhancers have the
unique ability to act across long distances and in an orientation
independent manner, interacting with factors to enhance
transcription [11]. Mechanistically, these elements function by
recruiting sequence-specific transcription factors and co-
activator complexes and delivering them to distally located
promoters throughout the genome. They are generally
protected from CpG methylation, creating an accessible
chromatin configuration for transcription factor binding and
long-range promoter interactions [12,13]. Recent global high
throughput technologies, including next generation sequencing
chromatin immunoprecipitation assays (ChIP-seq), have
advanced the identification and biology of enhancer elements
[14,15]. Enhancers can be identified by a H3K4 methylation
signature comprising higher amounts of H3K4
monomethylation (H3K4me1) and lower amounts of H3K4
trimethylation (H3K4me3) [16,17]. Additional subclasses of
active, intermediate and poised H3K4me1-enriched enhancers
have been identified based on their differential co-association
with H3K27 acetylation (H3K27ac), H3K9ac, H3K4me2,
H3K4me3, H3K27me3, RNA polymerase II (RNAPII), and the
histone acetyltransferase, p300 [18–24].
Recent studies indicate that active enhancers produce
noncoding RNA transcripts, termed enhancer RNAs (eRNAs)
[21,25–28]. These transcripts are typically non-polyadenylated,
less than 2000 nucleotides in length, not spliced, and their
nuclear localization suggests a role in transcriptional processes
[26,29]. It has been proposed that active enhancers may also
be promoters regulating noncoding RNA expression in addition
to their enhancer function [30,31]. Recent studies propose that
eRNAs bind transcriptional co-activators and chromatin
modifying complexes, mediate chromatin looping of enhancer
elements with promoters in cis, and provide a structural
scaffold for factors that regulate chromatin and gene
expression [25,26,29]. Alternatively, the eRNAs might result
from collisions of RNAPII with genomic regions or RNAPII
interactions during long distance looping of enhancers to
promoters [32]. Nonetheless, the function and biological roles
of eRNAs remains to be determined.
Transcription of the primary miR-200b~200a~429 transcript
is controlled by a well defined transcriptional start site (TSS),
located approximately 4kb upstream from the miR-200b hairpin
[4]. The promoter is sufficient for expression of
miR-200b~200a~429 in epithelial cells. MiR-200b~200a~429
gene silencing in mesenchymal cells occurs through the
binding of transcriptional regulators, ZEB1 and ZEB2, to
specific E-box elements located proximal to the TSS [4–9].
Recently, we and others have shown that the promoter is
subject to Polycomb Group (PcG)-mediated gene repression
via recruitment of the EZH2 and SUZ12 subunits [33–36].
Unlike most other miRNA genes, miR-200b~200a~429 resides
within an intergenic region that has a higher than average GC
content (>60%). The genomic architecture of the locus, which
comprises repetitive DNA elements, CpG islands, and DNaseI
hypersensitivity sites, is characteristic of PcG target genes but
also suggest that additional regulatory sequences might exist.
This is highly likely given the spatiotemporal characteristics of
miR-200b~200a~429 expression during development and its
well established functions in epithelial cell biology.
To further understand the transcriptional control of
miR-200b~200a~429 in epithelial cells, we have identified
novel sequences within the locus that regulate its expression.
An enhancer region was identified ~5.1kb upstream of the
miR-200b~200a~429TSS, which increased
miR-200b~200a~429 expression in epithelial cells. The
enhancer was transcribed in breast epithelial and
mesenchymal cell lines. The production of the enhancer-
transcribed RNA transcript, referred to as miR-200b eRNA,
was detected in breast epithelial and mesenchymal cell lines,
as well as numerous different cell types including fibroblasts
and hematopoietic cells, and did not correlate with the
miR-200b~200a~429 expression pattern. Our results indicate
that the miR-200b~200a~429 enhancer is important for the
level of miR-200b~200a~429 expression in breast epithelial
cells.
Results
An active chromatin domain upstream of
miR-200b~200a~429 functions as an enhancer in breast
cancer cells
Given that the miR-200b~200a~429 locus comprises a CpG
island located approximately 5 kilobases (kb) upstream of the
TSS of miR-200b~200a~429, we hypothesized that it might
function as an enhancer element. We therefore examined
whether the region surrounding this particular CpG island was
associated with the enhancer chromatin signature
[16,18,21,23]. HMLE human mammary epithelial cells
maintained in HuMEC media were induced to undergo EMT by
culturing them in serum-containing media and Transforming
Growth Factor-β1 (TGF-β1) for approximately 14 days
[2,36,37]. During this 2 week period, HMLE cells lost their
epithelial traits and acquired mesenchymal characteristics
showing increased cell motility and migration, and an EMT
gene signature. These cells were referred to as mesenchymal
HMLE (mesHMLE) cells. Chromatin immunoprecipitation
assays coupled to next generation sequencing (ChIP-seq) was
carried out on the HMLE and the mesHMLE cells and analysis
of the data revealed the expected correlation of activating and
silencing histone modifications with gene expression at the
miR-200b~200a~429TSS on chromosome 1 [36]. At
approximately 5 kb upstream of the TSS, we detected the
presence of an active enhancer chromatin signature
comprising H3K4me1, H3K4me3, H3K9/14ac and H3K27ac in
both cell types. Intriguingly, the H3K27me3 mark that covered
the TSS in mesHMLE cells did not spread into the active
enhancer-like chromatin domain, suggesting the region
Transcriptional Regulation of miR-200b~200a~429
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remained in an accessible chromatin configuration following
miR-200b~200a~429 gene silencing (Figure 1A-B). This notion
was further supported by the observation that CpG methylation
was absent at the upstream region (Figure 1C-D). The active
enhancer chromatin domain was confirmed in independent
ChIP-qPCR assays (Figure S1A-B). Similar results were
observed in the MDA-MB-468 (epithelial) and MDA-MB-231
(mesenchymal) cell lines indicating that the enhancer
chromatin signature was not specific to the HMLE cell lines
(Figure S1).
Figure 1.  An active chromatin domain is located upstream of the miR-200b~200a~429 locus.  Normalized ChIP-seq signal
profiles were generated for H3K4me1, H3K4me3, H3K9/14ac, H3K27ac and H3K27me3 at the miR-200b~200a~429 locus
(chr1:1,090,000-1,105,000) in (A) epithelial HMLE cells and (B) mesenchymal HMLE that have undergone EMT. The x-axis shows
the distance in kilobases (kb) relative to the TSS (designated 0), the chromosomal coordinate marking the TSS is indicated and a
schematic diagram of the primary miR-200b~200a~429 transcript is positioned boxes indicate the mature miRNA hairpin transcripts.
The y-axis shows the sequencing coverage per million reads for each histone modification normalized to the Input control sample.
(C) CpG methylation analysis of the miR-200b~200a~429 locus in epithelial HMLE cells (left panel) and in mesenchymal HMLE
cells following 46 days of TGF-β1 (right panel) treatment using Illumina HM450K methylation array [36]. An arrow marks the TSS.
The x-axis indicates the distance in kb from the TSS designated 0. The y-axis shows the % CpG methylation occurring at each
genomic region.
doi: 10.1371/journal.pone.0075517.g001
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To determine whether this region was acting as a
miR-200b~200a~429 enhancer element, we performed
transient dual reporter assays using a panel of truncated
miR-200b~200a~429 genomic segments driving firefly
luciferase expression. As expected, the minimal promoter
region (-321 to +19 relative to the TSS) produced luciferase
activity in HMLE cells but had little or no activity in the
mesHMLE cells (Figure 2A-B) [38]. In order to identify the
location of the predicted enhancer element, a series of reporter
constructs that spanned upstream to -5771 relative to the TSS
were created (Figure 2A). Insertions to -3877 had little effect on
activity over levels observed for the minimal promoter, but the
larger genomic segments, -4611/+19 and -5771/+19, resulted
in higher levels of transcriptional activity. The larger constructs,
-5771/+19 and -4611/+19 respectively, provided ~27 fold and
~15 fold higher activity compared to the construct containing
only the minimal promoter region. Therefore, the enhancer
could be mapped between -5771 and -4611 relative to the
TSS, with some enhancer activity also observed between
-4611 and -3877. We then cloned the predicted enhancer
(-5771/-4607 ENH) in both orientations (sense and anti-sense)
upstream of the minimal miR-200b~200a~429 promoter region
to create PRO&ENH and PRO&ENH (-) constructs. Both
constructs generated a higher level of reporter activity (~ 20
fold) compared to the minimal promoter region (-321/+19 PRO)
(Figure 2B-C), and this activity was observed only in the
epithelial HMLE cells. Reporter genes in which the predicted
enhancer (-5771/-4607 ENH) placed in either direction
upstream from the luciferase gene (ENH and ENH(-)) were
also tested for activity. Consistent with other previously
described enhancers, the constructs showed similar activity
suggesting that the enhancer also acts as a bi-directional
promoter (Figure 2C) [28,30,39,40]. Interestingly, the enhancer
activity was detected in both cell types suggesting that the
minimal promoter was responsible for epithelial-specific
transcription while the enhancer further increased
transcriptional activity of the promoter in these cells. Taken
together, these experiments confirmed that a constitutive
enhancer exists at ~5.1kb upstream of the
miR-200b~200a~429 minimal promoter and contributes to the
activity of the miR-200b~200a~429 promoter in an orientation-
independent manner.
miR-200b eRNA is transcribed from the enhancer
region of the miR-200b~200a~429 locus
The observation that the miR-200b~200a~429 enhancer
acted as a promoter in the HMLE and mesHMLE cells,
prompted us to investigate whether this region was also
capable of producing RNA. Indeed, enhancers have shown
evidence of non-coding RNA production (>200 nucleotides),
termed enhancer RNA (eRNA), in a diverse range of
mammalian cell types including neural progenitors, human cell
lines, and embryonic stem cells [21,25,41,42,28]. To
investigate this possibility, we performed qRT-PCR analysis to
search for transcripts derived from the region surrounding the
enhancer (Figure 3A). A RT-PCR product was obtained from
HMLE and mesHMLE cell cDNA primed with random hexamer
but not oligo dT, using primers designed at position -5.1kb
upstream of the TSS of miR-200b~200a~429 (Figure 3B and
data not shown). Furthermore, this analysis revealed that a
significant level of transcription occurred at the -5.1kb position
whereas the surrounding intergenic regions contained no
detectable transcripts by PCR except for the miR-200b~a~429
pri-miR. Furthermore, the expression level of the transcript
while low, was similar to the well-characterized long noncoding
RNA, HOTAIR as well as the pri-miR-200b~200a~429
transcript (Figure 3B). Quantitative RT-PCR analysis of cDNA
synthesized with strand specific gene specific primers for the
enhancer region revealed the production of both sense and
antisense RNA transcripts in the HMLE and mesHMLE total
RNA fractions (Figure S2). We detected increased amounts of
the sense transcript (~5 and ~8 fold higher in HMLE and
mesHMLE cells, respectively) compared to the antisense
transcript. This analysis revealed bidirectional RNA production
at the enhancer and in both cell types, and an
overrepresentation of the sense transcript.
To locate the start and end of the major sense transcript we
performed 5’-RACE PCR and 3’-RACE PCR on DNaseI-treated
total RNA isolated from HMLE and mesHMLE cells, and also
from MDA-MB-468 and MDA-MB-231 breast cancer cells.
Because the RT-PCR we had performed indicated the
transcript was not polyadenylated, we poly(A) tailed the RNA in
vitro, prior to the 3’ RACE analysis. To efficiently identify the
transcript start and end sites in the various cell lines, we
prepared a bar code library using the combined RACE
products from each cell line, and sequenced them as a pool on
an Ion Torrent sequencer (RACE-seq) (Figure S3). We
obtained a total of 293,076 reads containing 29.53Mbp of
sequence. Approximately 63% of the reads could be correctly
assigned to a barcode/primer following the removal of
incomplete reads, and of these, 96.8-98.7% mapped to the
expected region on chromosome 1 (Figure 3C). This analysis
showed the most frequent TSS in all 4 cell lines corresponded
to the C located 5185 bp upstream of the miR-200b~200a~429
pri-miR start site, but with additional heterogeneous start sites
arising nearby. The transcript 3’ end was more homogeneous
but varied somewhat between cell lines, being located at -5000
relative to the miR-200b~200a~429 pri-miR start site in HMLE
cells, but at other nearby locations in the other cell types
(Figure 3C). The novel RACE-seq technique employed here,
unlike more traditional RACE techniques involving sequencing
of individual clones, revealed a comprehensive collection of
transcripts of variable transcription start and end sites. The
multiple start sites for the transcript were consistent with
previous observations showing that CpG island promoters were
associated with more than one initiation motif [43,44]. BLAST
searches revealed no sequence similarity to any other regions
of the human genome. No polyadenylation signals were
present in the vicinity of the 3’ ends, consistent with the
observation that the transcript could be reverse transcribed
using random primers but not oligo(dT) primer (Figure 3C and
data not shown). The transcripts were GC rich, revealing an
average GC content of 63% (Figure S4). This analysis thus
revealed the presence of a RNA transcript of variable size but
with a consensus of ~180 nucleotides in human epithelial and
mesenchymal cell lines. We refer to this transcript as miR-200b
Transcriptional Regulation of miR-200b~200a~429
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eRNA to acknowledge its production from the -5.1kb
miR-200b~200a~429 enhancer element.
Lack of correlation between miR-200b eRNA and
miR-200b~200a~429 expression patterns
Although the relationship between enhancer function and
transcription across an enhancer is currently unclear, there is
some evidence that eRNAs are functional and have roles in
regulating transcription of genes in cis [41]. It has been shown
that eRNAs can affect transcription both positively and
negatively [31]. We therefore compared the expression pattern
of miR-200b eRNA with miR-200b~200a~429 gene cluster and
other epithelial (E-Cadherin) and mesenchymal (ZEB1) genes
in a panel of breast cancer cell lines. We used GAPDH as a
normalization control gene because the levels of this
housekeeping gene did not change in EMT (Figure S5). As
shown in Figure 4A, miR-200b eRNA was expressed at varying
levels in the epithelial and mesenchymal cell types. By
Figure 2.  Identification of an upstream enhancer region that increases the transcription of the miR-200b~200a~429
promoter in epithelial breast cancer cells.  (A) A series of 5’ deletions of the human miR-200b~200a~429 locus comprising the
promoter and potential enhancer were cloned into a firefly luciferase reporter plasmid. (B) The reporter plasmids were transiently
transfected along with the Renilla pTK vector into epithelial HMLE cells (white bars) or mesenchymal HMLE cells (black bars).
Luciferase activity was assayed approximately 48 hours later using the Dual-Luciferase Reporter Assay System (Promega). Data
are expressed as normalized luciferase activity and represent means ± SD of at least four independent experiments. (C) The
enhancer region (-5771/-4607 ENH) was cloned in both directions immediately upstream of the minimal miR-200b~200a~429
promoter (-321/+19 PRO) or the Luciferase coding region creating PRO&ENH and ENH as well as PRO&ENH (-) and ENH (-) with
ENH oriented in the sense and antisense orientation, respectively. Luciferase activity was assay as described in (B).
doi: 10.1371/journal.pone.0075517.g002
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Figure 3.  miR-200b eRNA is transcribed from the upstream intergenic enhancer region of miR-200b~200a~429.  (A)
Schematic representation of the miR-200b~200a~429 locus. Black box indicates the position of the potential enhancer. A black
arrow marks the TSS direction of the primary miR-200b~200a~429 transcript. Grey boxes indicated the mature miR-200b, miR-200a
and miR-429 genes. Black bars indicate the positions (in kilobases, kb) of the PCR primers used for qRT-PCR. (B) Expression
levels of HOTAIR, miR-200b eRNA and the primary miR-200b~200a~429 transcript as determined by qRT-PCR in epithelial and
mesenchymal HMLE cells using random hexamer primed cDNA synthesized from total RNA. The x-axis shows the distance from
the miR-200b~200a~429 TSS in kb. Data represents mean ± SD of three independent experiments. (C) Schematic representation
of the enhancer region located relative to the miR-200b~200a~429 TSS. Boxes indicate the locations of PCR amplicons used to
detect the miR-200b eRNA in Figure 3B. RACE PCR primers and their start locations relative to the miR-200b~200a~429 are
indicated. 5’ and 3’ RACE-seq analysis of the miR-200b eRNA with cDNA prepared from total RNA of HMLE, mesHMLE, MDA-
MB-468 and MDA-MB-231 cells as described in the Materials and Methods. 5’ and 3’ ends of the miR-200b eRNA transcript are
mapped as % total reads for each cell line with extreme 5’ and 3’ ends indicated by colored arrows below. A consensus miR-200b
eRNA transcript is indicated.
doi: 10.1371/journal.pone.0075517.g003
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contrast, the miR-200b~200a~429 and E-Cadherin genes were
restricted to epithelial cell lines, while the mesenchymal cell
types exclusively expressed ZEB1. Consistent with other
described eRNAs, the expression level of miR-200b eRNA was
low (Ct values 26-28) [25,41]. In contrast, the expression levels
of the ZEB1 and E-cadherin mRNA transcripts were
substantially higher (13 and 112 fold respectively) with Ct
values ranging from 20-24 using equally efficient qRT-PCR
primers. Thus, our analysis revealed that miR-200b eRNA did
not correlate with the miR-200b~200a~429 gene cluster
expression pattern.
We next determined whether the expression level of
miR-200b eRNA changed during EMT as modeled by the
HMLE in vitro system [2,37]. At various time points during the 2
week transition period, cells were harvested and analyzed for
changes in expression of the miR-200b eRNA transcript
(Figure 4B). We found that the expression level increased
approximately 2 fold following exposure to TGF-β1 for 8 days
and this level was maintained in the longer term mesenchymal
cultures (>18 days of exposure to TGF-β1). To further
investigate the role of miR-200b eRNA in transcriptional
regulation, we performed sub-cellular fractionation of the HMLE
and mesHMLE cells. The analysis revealed that the miR-200b
eRNA was predominately found in the nuclear fraction rather
than the cytosol (Figure 4C). This result was consistent with
recent publications showing eRNAs are predominately located
in the nucleus [41]. Taken together, these results indicated that
miR-200b eRNA is a nuclear non-coding RNA that is weakly
induced during an early phase of transition to the mesenchymal
cell state.
Analysis of the effect of miR-200b eRNA on the
transcriptional activity of the miR200b~200a~429
promoter region
To investigate the role of miR-200b eRNA in gene regulation,
we custom designed siRNAs against the predominating
miR-200b eRNA transcript targeted by four different
sequences. Initial experiments were performed to test whether
the cellular level of miR-200b eRNA was decreased by the
siRNAs targeting the transcript but effective knockdown was
not achieved (Figure S6). Similar data was obtained for other
cell lines including MDA-MB-468, mesHMLE and MDA-MB-231
cells (data not shown). Additional siRNAs could not be
designed and tested from other manufacturers due to the high
GC content and relatively short sequence length (<200
nucleotides). In the qRT-PCR surveys of different human cell
types and tissues, we found that the miR-200b eRNA was
expressed in all cell types analyzed including human
fibroblasts, T cells and bone marrow-derived cells (Figure S7).
Thus, we decided to over-express miR-200b eRNA and assess
the effect of increased levels of miR-200b eRNA on
miR-200b~200a~429 promoter activity in epithelial and
mesenchymal HMLE cells, as well as other breast cancer cell
lines.
To investigate whether miR-200b eRNA was capable of
regulating transcription of miR-200b~200a~429 in trans, we
conducted luciferase reporter gene assays. For these
experiments, we employed the miR-200b luciferase reporter
plasmids (Figure 2A), pcDNA over-expression vectors
comprising the miR-200b eRNA transcript (Materials and
Methods) and ZEB1 and ZEB2 expression vectors as a control
[4]. Over-expression of miR-200b eRNA in HMLE cells resulted
in ~100 fold increase in expression compared to endogenous
eRNA transcript levels in these cells (Figure S8). In HMLE cells
that express miR-200b~200a~429, we found that ZEB1/2 over-
expression inhibited miR-200b~200a~429 minimal promoter
(PRO) activity, whereas over-expression of miR-200b eRNA
had little or no effect on PRO activity (Figure 5). Similar trends
were observed in the context of the entire locus (LOCUS) and
the enhancer fused to the minimal promoter (PRO&ENH). Co-
transfection with either the ZEB1/2 or eRNA constructs in
mesHMLE cells with the promoter constructs had no effect on
reporter activity. By contrast, we found that ZEB1/2 over-
expression stimulated the activity of the enhancer-only (ENH)
reporter construct in both HMLE and mesHMLE cells, while
miR-200b eRNA stimulated the enhancer-only reporter in
HMLE but not mesHMLE cells (Figure 5). The reporter gene
assays were also conducted in the respective epithelial and
mesenchymal cell lines, MDA-MB-468 and MDA-MB-231,
which provided similar results (Figure S9). However, in MDA-
MB-468 cells, over-expression of ZEB1/2 and miR-200b eRNA
caused no change in activity of the ENH reporter construct
(Figure S9). Furthermore, over-expression of miR-200b eRNA
in HMLE and mesHMLE cells did not induce EMT/MET nor did
it lead to changes in miR-200b~200a~429 and EMT/MET-
affiliated gene expression patterns (Figure S10; data not
shown).
Overall, these results provide evidence that enforced
expression of the miR-200b eRNA transcript does not influence
miR-200b~200a~429 and EMT-affiliated gene expression
patterns nor does it affect the maintenance of the epithelial or
mesenchymal cell state. However, we cannot fully rule out the
possibility that the transcript regulates these processes
because depletion of miR-200b eRNA using targeted siRNAs
was technically unachievable. Furthermore, exogenous
miR-200b eRNA transcript was polyadenylated, due the use of
pcDNA3.1, which may have influenced the physiological
structure and function of the eRNA in vivo. Despite this, we
conclude based on the experimental data shown here that the
miR-200b~200a~429 enhancer element is important for optimal
miR-200b~200a~429 promoter activity, and produces a
noncoding eRNA transcript, whose function remains to be
determined.
Discussion
Epithelial cells undergo major changes in morphology and
migratory capacity as they transition into mesenchymal cells
during TGF-β1-mediated EMT. Such changes in cellular
function are proposed to result from chromatin reorganization
of the genome, allowing for the establishment and maintenance
of cell type specific gene expression signatures. A major player
in this process is the miR-200 gene family which is required for
maintenance of the epithelial cell state but becomes silenced in
mesenchymal cells, leading to increased cell motility,
proliferation and migration. Here, we have investigated the
Transcriptional Regulation of miR-200b~200a~429
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Figure 4.  Gene expression analysis of miR-200b eRNA, miR-200b~200a~429 and EMT-affiliated genes.  (A) Real-time PCR of
miR-200b eRNA, EMT markers and miR-200 genes in a panel of breast epithelial and mesenchymal cell lines. mRNA (top panel) is
normalized to GAPDH while miRNA (bottom panel) is normalized to U6 snRNA. Comparative quantitation was used to determine
expression profiles of the genes in the cell line panel. Expression of E-cadherin and miR-200b eRNA in HMLE cells is set to a value
of 1, whereas Zeb-1 is expressed relative to mesHMLE cells having a value of 1. Error bars represent mean ± SD of three
independent experiments. (B) Relative expression levels of miR-200b eRNA during EMT time course of HMLE cells treated with
TGF-β1 for up to 18 days. The realtime PCR data is normalized to GAPDH. Expression of miR-200b eRNA is set to a value of 1 in
HMLE cells (C) Relative concentration of miR-200b eRNA, U6, HOTAIR, GAPDH and βActin RNA transcripts in the nucleus and
cytoplasm of HMLE cells. Absolute quantitation was used to determine the expression level of each gene in the cytoplasmic and
nuclear fractions. Error bars represent mean ± SD of three independent experiments.
doi: 10.1371/journal.pone.0075517.g004
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existence of additional regulatory elements responsible for
controlling miR-200b~200a~429 expression in epithelial cells.
We identified an H3K4me1-enriched enhancer sequence
located roughly 5.1kb upstream of the
miR-200b~200a~429TSS, and classified it as an active
regulatory element based on its co-association with H3K4me3,
H3K27ac and RNAPII. The miR-200b~200a~429 enhancer
was functional in epithelial and mesenchymal cell types, and
produced a short non-coding RNA, miR-200b eRNA, linking
eRNA production to enhancer function. These findings indicate
that the miR-200b~200a~429 enhancer can increase the
expression from the minimal miR-200b~200a~429 promoter.
However the miR-200b~200a~429 promoter is responsible for
confining expression to epithelial cells.
Recent genome-wide ChIP-seq studies have revealed that
gene promoters associate with H3K4me3, whereas H3K4me1
is often found at enhancer elements but shows very little
association with H3K4me3 [16,18]. Although the classification
of enhancer elements in terms of chromatin modifications is in
the early stages, some general features have already emerged.
It has been proposed that H3K4me1-enriched enhancers can
be classified as either “active” or “poised” by the co-association
of additional histone modifications, namely, H3K27ac and
H3K27me3, respectively [20,23,24,31]. Active enhancers are
typically associated with RNAPII and H3K27ac whereas poised
enhancers often contain the repressive H3K27me3 mark but
lack RNAPII and H3K27ac. Our results suggest that the
miR-200b~200a~429 enhancer is maintained in a
transcriptional active or competent state given that the region
was occupied by an active enhancer signature in both epithelial
and mesenchymal cells. However, it remains to be determined
whether these marks are functionally important for
miR-200b~200a~429 enhancer activity or are of consequence
to the active enhancer state. It is currently unclear how these
histone marks are deposited and maintained at enhancers
during genomic processes such as nucleosome remodeling,
histone variant deposition and rapid histone turnover [45–47].
Nevertheless, it will be interesting to identify transcriptional
complexes that interact at the miR-200b~200a~429 enhancer
in future work.
More recently, enhancer elements have been shown to
produce non-coding RNA transcripts, termed enhancer RNAs
Figure 5.  Over-expression of miR-200b eRNA has no effect on miR-200b~200a~429 promoter activity in epithelial and
mesenchymal HMLE cells.  Schematic representation of the miR-200b~200a~429 luciferase reporter constructs, PRO (-321/+19),
LOCUS (-5771/+19), PRO&ENH (-321/+19 to -5711/4607) and ENH (-5711/-4607). The miR-200b~200a~429 reporters, pcDNA3.1,
pcDNA3.1 Zeb1, pcDNA3.1 Zeb2 or the pcDNA3.1 miR-200b eRNA plasmids, and the Renilla vector were co-transfected into
epithelial HMLE (white bars) or mesenchymal HMLE (black bars) cells. Transiently transfected cells were incubated for
approximately 24-48 hours. Data are normalized by Renilla luciferase activity and represent means ± SD of at least three
independent experiments.
doi: 10.1371/journal.pone.0075517.g005
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(eRNAs) [27,28,48], non-coding RNA-activator (ncRNA-a) [41]
and enhancer non-coding RNA (e-ncRNA) [21]. Their defining
features include lack of polyadenylation, an average size of
900 nucleotides, and the absence of transcript splicing [29]. At
a functional level, enhancer-transcribed RNAs have activating
or silencing roles in mRNA gene transcription. Some clear
examples include ncRNA-a7 transcribed from the Snai1
enhancer, Mistral noncoding RNA which is produced at the
HoxA locus [41,49], HOTTIP encoded at the HoxA enhancer
site [48], and eRNAs produced from p53-bound enhancer
elements [28]. The miR-200b eRNA described here can be
classed as a typical eRNA due to its lack of polyadenylation,
short length (~180 nucleotides) and lack of transcript splicing.
However, the functional role of miR-200b eRNA in controlling
miR-200b~200a~429 gene expression remains elusive.
Knockdown with siRNA was unsuccessful despite numerous
attempts at custom design and optimization of transient
transfection conditions. It is possible that the presence of
antisense miR-200b eRNA could have prevented efficient
siRNA knockdown of the sense transcript. However, the level
of the antisense transcript was lower (~5-8 fold reduced) than
the sense miR-200b eRNA, and we performed extensive
individual and pooled siRNA titrations in order to optimize the
targeting of siRNAs to the sense miR-200b eRNA transcript.
Thus, we concluded that the relatively small target sequence
(~180 nucleotides), GC rich sequence content, presence of the
antisense transcript and mainly nuclear localization impaired
effective knockdown of miR-200b eRNA using siRNAs.
Improvements in siRNA delivery to the nucleus, custom design
software and/or specific modified strand specific DNA
oligonucleotides may increase the likelihood of finding an
effective knockdown approach for short GC-rich target
sequences such as the one described here.
The mechanism of enhancer regulation of gene expression
and regulation of enhancer elements themselves is
fundamental to understanding gene transcriptional control.
Given our finding that the upstream miR-200b~200a~429
enhancer element increases miR-200b~200a~429 expression
in epithelial cells, a next key question will be how this element
works in concert with the promoter, presumably through
chromosomal looping, which could facilitate the recruitment of
transcriptional complexes. Another important question will be
why the miR-200b~200a~429 enhancer element also behaves
like a promoter, producing its own RNA. In this study, the
biological function of the miR-200b eRNA remained
unresolved. However, it is tempting to speculate that the
constitutive production of the miR-200b eRNA maintains an
transcriptionally competent locus during EMT, thus allowing for
rapid reactivation of the miR-200b~200a~429 promoter when
mesenchymal cells revert back to an epithelial cell state during
MET. Further elucidation of the miR-200b~200a~429 enhancer
element and miR-200b eRNA function should bring about new
insights into the role of enhancers and regulation of gene
transcription in EMT and breast cancer metastasis.
Materials and Methods
Cell line maintenance
HMLE cells were cultured in HuMEC ready media (Gibco)
while other human breast cancer cell lines were cultured as
previously described [4]. To induce EMT and generate
mesHMLE cells, HMLE cells were cultured for at least 14 days
in DMEM: F12 media (1:1) supplemented with 10 µg/ml insulin,
20 ng/ml EGF, 0.5 µg/ml hydrocortisone, and 5% fetal calf
serum (FCS) and treated with 2.5 ng/ml of TGF-β1 (R&D)
[2,36,37].
Generation of miR-200b~200a~429 promoter and the
pcDNA3 miR-200b eRNA constructs
A -5771/+19 genomic region containing the
miR-200b~200a~429 promoter [4] was amplified by PCR using
Pfu DNA polymerase (Promega) and directionally cloned into
the pGL3-basic (Promega) reporter using NheI and BglII sites
generating the -5771/+19 construct. Subsequent promoter
truncations were amplified from this template and cloned in a
similar manner which resulted in the -4611/+19, -3877/+19,
-3358/+19, and -2910/+19 constructs. The -321/+19 (PRO) and
-1574/+19 constructs were utilized as previously described
[38]. The PRO&ENH construct was made by excising
intervening sequence (-322 to -4608) from construct -5771/+19
using BamHI sites that resulted in placing the enhancer region
(-5711/-4607) in sense and antisense orientation directly
upstream to the minimal promoter region (PRO -321/+19). The
enhancer only (ENH) -5711/-4607 construct was made by PCR
and cloning into pGL3-basic using a single KpnI site in order to
create clones with sense and antisense orientation of the
enhancer region. The pcDNA3.1 miR-200b eRNA expression
construct was made by PCR amplification of the 185 bp eRNA
sequence spanning -5209 to -5023 relative to the putative TSS,
and directional cloning into pcDNA3.1 using HindIII and BamHI
sites. Constructs were confirmed using pyrosequencing of
plasmid DNA.
Transfection and reporter assay
For reporter assays, cell lines were plated in 24 well plates
and co-transfected with 5 ng pRL-TK Renilla plasmid
(Promega) and 200 ng miR-200b~200a~429 promoter firefly
luciferase reporter plasmids using Lipofectamine LTX
(Invitrogen). In Figure 5, 100 ng of the pcDNA3.1 empty vector,
ZEB1 and ZEB2 expression plasmids (pcDNA3.1-HisC-ZEB1
and pcDNA3.1-HisC-ZEB2; 50 ng each) or 100 ng of the
miR-200b eRNA expression plasmid (pcDNA3.1-miR-200b
eRNA) were also co-transfected. After 48 hr of incubation, cell
lines were either lysed in Trizol (Invitrogen) and RNA extracted
or lysed in passive lysis buffer (Promega) and luciferase
activity measured with the Dual-Luciferase Reporter Assay
System (Promega) using a Glomax-multi detection system
(Promega). All reporter assays are shown as normalized
luciferase activity (averaged ratios of Firefly luciferase:Renilla ±
SEM) and are representative of multiple experiments.
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siRNA transfection
For siRNA reporter experiments, individual or mixtures of
four siRNAs (Dharmacon) of human miR-200b eRNA were
transfected into cells using HiPerFect (Qiagen) at 10, 50 and
100nM each, then repeat-transfected 48 hr later with the same
siRNAs. RNA was harvested after a further 24-48 hr followed
by real-time PCR analysis of random hexamer primed cDNA.
Target sequences of the miR-200b eRNA siRNA were the
following: siRNA#1 GCT GAC TAG AGG AGG CAA A;
siRNA#2 CCA GGG TTC TCC AAG CAA A; siRNA#3 CGC
CGA GGA GAC TGG GTT TT; and siRNA#4 AAG CAA AGC
CTG TCT GTG TT. The ON-TARGETplus non-targeting smart
pool negative control (Dharmacon) was used as a negative
control.
Isolation of RNA and real-time PCR
Total RNA was extracted from cell lines and purified using
Trizol (Invitrogen). Real-time PCR was performed as previously
described [5]. Briefly, for mRNA measurements, cDNA was
synthesized using a QuantiTect Reverse Transcription Kit
(Qiagen) and real-time PCR was performed using QuantiTect
SYBR, Green PCR kit (Qiagen) with primers as listed (Tables
S1-S2). MicroRNA PCRs were performed using TaqMan
microRNA assays (Life Technologies) (Table S3). Real-time
PCR data for mRNA and microRNA were expressed relative to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or U6
snRNA, respectively. Quantitation was performed using a
Rotor-Gene 6000 (Qiagen).
5’ RACE
5’ RACE was performed using the 5’ RACE system for Rapid
amplification of cDNA Ends, Version 2.0 (Invitrogen) according
to the manufacturer’s instructions. Briefly, 3 µg total RNA was
treated with DNaseI (Ambion). First strand cDNA synthesis was
performed using the 5’ A miR-200b eRNA custom designed
gene specific primer. The cDNA was purified using a S.N.A.P.
column (Invitrogen) then a poly(C) tail was added to the 3’ end
of the cDNA using TdT and dCTP. The dC-tailed cDNA
underwent two rounds of PCR amplification using nested eRNA
specific primers (5’ B and 5’ C) together with universal
amplification primers and Taq Advantage 2 polymerase
(Clontech). PCR products were checked on a 2% Agarose gel
following each round of PCR amplification. Sequences of the
three gene specific primers are listed in Table S4.
3’ RACE
3’ RACE was performed using the 3’ RACE system for Rapid
amplification of cDNA Ends (Invitrogen) according to the
manufacturer’s instructions using the recommended modified
method for transcripts with high GC content. Briefly 3 µg of total
RNA was treated with DNaseI (Ambion) then polyadenylated
using a poly(A) Tailing Kit (Ambion). First strand cDNA
synthesis was initiated at the poly(A) tail using an Adapter
primer. Three rounds of nested PCR amplification of the
miR-200b eRNA cDNA was performed with custom designed
gene specific primers (3’ A, 3’ B and 3’ C) and Universal
Adapter Primers using Taq Advantage 2 polymerase mix
(Clontech). PCR products were checked on a 2% Agarose gel
following each round of PCR amplification. Sequences of the
three gene specific primers are listed in Table S4.
RACE-seq
A sequencing library was prepared using an Ion Plus
Fragment Library Kit (Life Technologies) following the
manufacturers recommended protocol with the exception that
all PCR product clean-up was column based using a QIAquick
PCR purification kit (Qiagen). For each cell line, equal amounts
of 5’ & 3’ RACE products were pooled (~50 ng total). The
RACE PCR pool was purified using a QIAquick PCR
purification kit (Qiagen) then underwent end repair (Ion Plus
Fragment Library kit). End repaired RACE PCR products were
then purified using QIAquick PCR purification columns before
Adapter ligation (Ion Xpress P1 adapter & Ion Xpress Bar code
adapters 5-8 from Ion Xpress Bar code Adapters 1–16 Kit) (Life
Technologies) using a different bar code adapter for each cell
line pool. Ligation was followed by nick repair to complete the
linkage between the adapters and DNA inserts using reagents
from the Ion plus Fragment library kit. Libraries were purified
using the QIAquick PCR purification kit (Qiagen) before being
checked for integrity & size on a Bioanalyzer (Agilent
Technologies). The libraries were gel purified on a 2% Agarose
gel selecting fragments > 150bp to remove contaminating
unincorporated adapters, and purified using a QIAquick gel
extraction kit (Qiagen). The size fractionated library was then
PCR amplified (using primers and reagents from the Ion Plus
Fragment Library kit) for 5 cycles to select for P1-X
combination of ligated ends suitable for sequencing. The PCR
amplified libraries were purified a final time using QIAquick
PCR purification kit (Qiagen) before being checked on a
Bioanalyzer (Agilent Technologies) and equal amounts of each
individual library were combined into a single library pool. The
library pool was clonally amplified on Ion Sphere Particles
using the Ion PGM 200 Xpress Template kit prior to loading on
an Ion 314 chip and sequencing on the Ion Torrent PGM (Life
Technologies) using 130 cycles. Sequences obtained from
each cell line were identified using their unique bar codes. For
each sequencing read, the bar codes were read, trimmed &
products put into 4 bins (corresponding to each cell line RACE
pool) for subsequent analysis. The Ion Torrent library
preparation adapters and the poly(n) sequences and adapters
added during the RACE protocol were removed leaving specific
sequences corresponding to either 5’ or 3’ RACE products.
These sequences were mapped to the human hg19 reference
genome, and 5’ or 3’ ends of each transcript were identified.
The raw and processed data files can be downloaded from
https://bitbucket.org/sacgf/attema_2013_200_enhancer.
DNA methylation analysis
Genomic DNA was isolated from cells using either DNeasy
Blood & Tissue kit (Qiagen), Trizol, or phenol chloroform
ethanol precipitation method (Invitrogen). 0.5 to 2 µg genomic
DNA was bisulphite modified with the EZ DNA Methylation-
Gold Kit according to the manufacturer’s protocol (Zymo
Research). Bisulphite-modified genomic DNA was used for
hybridization on Infinium HumanMethylation 450 BeadChip,
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following the Illumina Infinium HD Methylation protocol, and the
BeadChip was scanned using an Illumina HiScan SQ scanner
(Illumina, San Diego, CA, USA). The methylation score for
each CpG was represented as a β-value according to the
fluorescent intensity ratio. β-values may take any value
between 0 (non-methylated) and 1 (completely methylated).
ChIP-qPCR
ChIP assays using 1 x 106 cells per reaction were performed
as recently described [36]. Antibodies included anti-histone H3
(ab1791; Abcam), and anti-trimethyl histone H3K4 (ab8580;
Abcam), anti-monomethyl histone H3K4 (ab8895; Abcam),
anti-acetyl histone H3K9/14 (06-599; Millipore), anti-acetyl
histone H3K27 (07-449; Millipore), anti-trimethyl histone H3K27
(abcam ab6002) and anti-RNA Polymerase II Phospho S2 and
S5 (ab5131; ab5095; Abcam). Briefly, 6 x 106 cells were
crosslinked in 1% formaldehyde for 10 min at room
temperature with gentle rocking or inversion every 2-3 min.
Cells were quenched with 0.25M Glycine, pelleted by
centrifugation (300 rcf for 5 min), and washed twice in ice-cold
1x HBSS (Gibco) containing protease inhibitor cocktail
(Roche). The cells were lysed in 300 µl of lysis buffer (10 mM
Tris pH 7.5/1mM EDTA/1% SDS) containing PIC and incubated
on ice for 10 min. After lysis, 900 µl of 1x HBSS containing PIC
was added and 200 µl was aliquoted into 6 individual tubes.
Each 200 µl aliquot was sonicated by using a bioruptor®
sonicator (Diagenode), which was empirically determined to
give rise to genomic fragments ~500bp. The soluble chromatin
was collected by 4°C ultracentrifugation (13,000 rpm for 5 min)
and pooled into a new 15ml falcon tube. The supernatant was
diluted 2-fold with 2x RIPA buffer (10 mM Tris-HCl pH 7.5; 1
mM EDTA; 1% Triton X-100; 0.1% SDS; 0.1% sodium
deoxycholate; 100 mM NaCl; PIC), 1/10 volume (40 µl) input
was removed, and 400 µl of soluble chromatin (equivalent to 1
x 106 cells) was distributed to new Eppendorf tubes. Each
respective antibody was added at appropriate amount as
tested in titration experiments using control promoters.
Immunoprecipitations were performed for 2 h at 4°C with
rotation, and antibody: protein:DNA complexes were then
collected with 50 µl of protein A and/or G Dynabeads
(Invitrogen) for 2 h of rotation. The beads were washed three
times using 200 µl of RIPA buffer and once with TE buffer, then
incubated with 200 µl of fresh elution buffer with Proteinase K
for 2 h in a thermomixer (1300 rpm, 68°C) to reverse the
protein:DNA cross-links. After incubation, eluates were
collected into new eppendorf tubes. Genomic DNA was
recovered by using phenol chloroform extraction and ethanol
precipitation. Pellets were washed in 70% ethanol, briefly air-
dried, and resuspended in TE (10 mM Tris pH 7.5; 0.1 mM
EDTA) buffer. Quantitation of ChIP DNA (relative enrichment)
was performed using a Rotor-Gene 6000 (Qiagen) with
QuantiTect SYBR green PCR Kit (Qiagen) and ChIP qPCR
primer sequences as listed in Table S5. Enrichment of histone
modifications at genomic regions were expressed as % input
normalized to respective cell type histone H3 levels. % Input
was calculated using the formula % (ChIP/Input) = 2(Ct(ChIP) -
Ct(Input)) x Input Dilution Factor x 100% to account for chromatin
sample preparation differences.
ChIP-seq
For ChIP-seq experiments, the individual or pooled (n=3)
ChIP samples were submitted to Geneworks Pty Ltd (Adelaide)
for the ChIP-seq full service (library preparation and
sequencing). The library assembly was performed using the
TruSeq ChIP sample preparation kit (Illumina Inc.). ChIP DNA
libraries comprising single-ended 65bp long fragments directly
sequenced using a Genome Analyzer IIx (Illumina Inc.)
resulting in >20 million reads per sample. Sequencing reads
were aligned to the hg19 build of the human genome and
duplicate sequences were removed. Genomic DNA coverage
across the miR-200b~200a~429 locus
(chr1:1,090,000-1,105,000) was calculated as follows: read
coverage of experimental ChIP samples were calculated per
base pair (bp), normalized by sequencing depth, and
subtracted from the corresponding 10% Input control sample.
Average coverage was calculated over 50 bp regions. The
ChIP-seq data used for this study was extracted from a region
of chromosome 1 (chr1:1079434-1109285). The raw and
processed data files can be downloaded from https://
bitbucket.org/sacgf/attema_2013_200_enhancer.
Sub-cellular fractionation
Nuclear/cytoplasmic fractionation of epithelial and
mesenchymal HMLE cells was performed using hypotonic
buffers. Briefly, approximately 1 x 107 cells were harvested by
trypsin, washed with phosphate buffered saline (PBS) and
incubated for 10 min on ice in 900 µl of Hypotonic Buffer (10
mM HEPES-KOH (pH7.9), 10 nM KCl, 1.5 mM MgCl2, 1 mM
DTT, protease inhibitor cocktail tablet (Roche), and RNasin
(Ambion)). Forty five microlitres of 10% NP-40 was added, and
cells were pipetted up and down with a p1000 pipette 60 times,
and incubated on ice for 5 min. Cells were microcentrifuged for
5 mins at 4000 rpm at 4°C. Supernatant comprising the
cytoplasmic fraction was collected and stored at -80°C until
further processing for total RNA or protein. The nuclei pellet
was then washed in 500 µl of Hypotonic Buffer three times and
finally resuspended in 300 µl nuclear lysis buffer (20 mM
HEPES-KOH (pH7.9), 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 1 mM DTT, 5% glycerol, protease inhibitor cocktail
(Roche), and RNasin (Ambion), and incubated for 30 min on
ice. The nuclear pellet was microcentrifuged for 10 min at
13000 rpm at 4°C and the supernatant containing the nuclear
fraction was collected and stored at -80°C until further
processing for total RNA or protein. The concentration of total
RNA derived from the nuclear and cytoplasm were quantified
using the Nanodrop ND-1000 spectrometer (Nanodrop
Technologies) and normalized prior to cDNA synthesis using
Superscript III Reverse Transcriptase (Invitrogen). The amount
of cDNA in each fraction was determined by real-time PCR
using a Rotor-Gene 6000 (Corbett Life Science) with
QuantiTect SYBR green PCR Kit (Qiagen). Real-time PCR
primers are listed in Table S1.
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Supporting Information
Figure S1.  An active chromatin domain upstream of the
miR-200b~200a~429 locus confirmed by ChIP-qPCR
analysis. Representative ChIP-qPCR analysis of H3K4me1,
H3K4me3, H3K9/14ac, H3K27ac and H3K27me3 at the
miR-200b~200a~429 locus (chr1:1,090,000 -1,105,000) in (A)
epithelial HMLE, (B) mesHMLE, (C) MDA-MB-468 and (D)
MDA-MB-231. The x-axis shows the distance up and
downstream relative to the TSS and a schematic diagram of
the primary miR-200b~200a~429 transcript is positioned to
scale. An arrow marks the TSS and shaded boxes indicates
the mature miRNA transcripts. The y-axis shows % Input of
histone H3 modifications normalized to unmodified histone H3.
(TIF)
Figure S2.  The miR-200b~200a~429 enhancer region
produces sense and antisense eRNA transcripts. Total
RNA was isolated from HMLE and mesHMLE cells. Following
DNaseI treatment, total RNA was converted to cDNA using
random hexamers, 5’ A RACE primer (complementary to the
sense RNA transcript) or 3’ A RACE primer (complementary to
the antisense RNA transcript) (Table S4). Real-time PCR
analysis of cDNA was performed using gene specific primers
for the eRNA (Table S1). GAPDH was used for normalization
and data was analyzed using the comparative quantitation
method shown as relative expression to HMLE random
hexamer primed cDNA (set to 1). Error bars represent mean ±
SD of two independent experiments.
(TIF)
Figure S3.  Schematic of the 5’ and 3’ RACE-seq
methodology. The RACE-seq method comprises three steps,
5’ and 3’ RACE, Library preparation and Sequencing. DNaseI-
treated total RNA isolated from HMLE, mesHMLE, MDA-
MB-231 and MDA-MB-468 was subjected to 5’ RACE by
incorporating three rounds of nested PCR using gene specific
primers (Table S3) (Step 1). 3’ RACE was performed in a
similar manner except that the DNaseI-treated total RNA was
first polyA tailed (E. coli Poly(A) Polymerase I) (Step 1). 5’ and
3’ RACE PCR products obtained from each cell type were
pooled into single reaction tube and subjected to library
preparation (Step 2). Individual libraries comprising RACE
products from each cell line (total of 4) were prepared using
sample-specific bar code adapters were then combined and
sequenced together (Step 3). Sequences obtained from each
cell type were identified using their unique bar codes. For each
sequencing read, the bar codes were read, trimmed and sorted
into 4 bins (corresponding to each cell line RACE pool). The
Ion Torrent library preparation adapters (pink bars) and the
poly(n) sequences and adapters added during the RACE
protocol (grey bars) were removed, leaving behind specific
sequences corresponding to either 5’ or 3’ RACE products
(black bars with either a red dot or blue dot representing the
respective transcript ends). These sequences were mapped to
the human hg19 reference genome and 5’ or 3’ ends were
identified.
(TIF)
Figure S4.  Schematic of the miR-200b eRNA transcript
and its genomic location on human chromosome 1. The
major 5’ and 3’ RACE-seq transcript occurring in epithelial
HMLE and mesHMLE cells is shown inset to the location of the
transcript produced at enhancer region on human chromosome
1 (hsa chr1:1,092,994-1,093,179). The GC content is indicated.
(TIF)
Figure S5.  GAPDH is suitable for use as a normalization
control gene in the HMLE EMT cell line model. Relative
expression levels of the housekeeping genes GAPDH, βActin
and β2-microglobulin in the HMLE and mesHMLE cells.
Following DNaseI treatment, the RNA was converted to cDNA
using random hexamers. Real-time PCR analysis of cDNA was
performed using gene specific primers. The data was analyzed
using the comparative quantitation method and is shown as
relative expression to HMLE (set to 1) for each mRNA tested.
Error bars represent mean ± SD of two independent
experiments.
(TIF)
Figure S6.  Custom designed siRNAs fail to knock down
miR-200b eRNA transcript. Four custom siRNAs were tested
in transient transfection assays for their ability to knockdown
miR-200b eRNA in HMLE cells. Individual and pooled siRNAs
(1-4) were assayed at 10 nM (top panel), 50 nM (middle panel)
and 100 nM (bottom panel). Following DNaseI treatment, the
RNA was converted to cDNA using random hexamers. Real-
time PCR analysis of cDNA was performed using gene specific
primers for miR-200b eRNA (Table S1). Quantitative RT-PCR
data is calculated using the comparative quantitation method
and is shown as relative expression to the control siRNA (set to
1) following GAPDH normalization. Error bars represent mean
± SD of three independent experiments.
(TIF)
Figure S7.  Gene expression analysis of miR-200b eRNA in
other cell types. Total RNA was isolated from HMLE,
mesHMLE, normal bone marrow cells (samples 1-3), W1-38
fibroblast cell line and the Jurkat T cell line. Following DNaseI
treatment, the RNA was converted to cDNA using random
hexamers. Real-time PCR analysis of cDNA was performed
using gene specific primers for miR-200b eRNA (Table S1).
GAPDH was used for normalization. Data was analyzed using
the comparative quantitation method and is shown as relative
expression to HMLE (set to 1). Error bars represent mean ± SD
of three independent experiments.
(TIF)
Figure S8.  HMLE cells transiently transfected with the
pcDNA miR-200b eRNA plasmid results in ~100 fold
increased expression level. Relative expression using the
comparative quantitation method of miR-200b eRNA in HMLE
cells set to 1 (non-transfected), HMLE cells transiently
transfected with the pcDNA control vector or the pcDNA
miR-200b eRNA overexpression vector. GAPDH was used for
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normalization, and error bars represent mean ± SD of three
independent experiments.
(TIF)
Figure S9.  Over-expression of miR-200b eRNA has no
effect on miR-200b~200a~429 promoter activity in MDA-
MB-468 and MDA-MB-231 breast cancer cell lines.
Schematic representation of the miR-200b~200a~429 reporter
constructs, PRO (-321/+19), LOCUS (-5771/+19), PRO&ENH
(-321/+19 to -5711/4607) and ENH (-5711/-4607). The
miR-200b~200a~429 reporters, pcDNA3.1, pcDNA3.1 Zeb1,
pcDNA3.1 Zeb2 or the pcDNA3.1 miR-200b eRNA plasmids,
and the Renilla vector were co-transfected into epithelial MDA-
MB-468 (white bars) or mesenchymal MDA-MB 231 (black
bars) cells. Transiently transfected cells were incubated for
24-48 hours. Data are normalized by Renilla luciferase activity
and are means ± SD of at least three independent
experiments.
(TIF)
Figure S10.  Expression levels of EMT-affiliated genes in
HMLE cells transfected with the pcDNA miR-200b eRNA
plasmid. (A) Relative expression levels of the (A) E-cadherin,
N-cadherin, Zeb-1, Zeb-2, Twist and Fibronectin or (B)
miR-200b, miR-200a and miR-429 in HMLE cells transfected
with pcDNA control vector or the pcDNA miR-200b eRNA
overexpression vector. Following DNaseI treatment, the RNA
was subjected to cDNA synthesis using random hexamers.
Data was analyzed using the comparative quantitation method
and is shown as relative expression to pcDNA control (set to
1). GAPDH was used for normalization, and error bars
represent mean ± SD of two independent experiments.
(TIF)
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